Martin J. Schlumberger - Publications

Rethinking prophylactic central neck dissection in clinically node-negative papillary thyroid cancer.

Journal: The lancet. Diabetes & endocrinology

Published: February 23, 2026

Post-Chornobyl thyroid papillary carcinomas display distinct past 131I exposure and radiation-associated carcinogenesis molecular signatures at low and high thyroid doses.

Journal: Scientific reports

Published: February 19, 2026

Type 2 Deiodinase in Cancer-Associated Fibroblasts is Required to Sustain Growth of Poorly and Undifferentiated Thyroid Cancer.

Journal: Thyroid : official journal of the American Thyroid Association

Published: December 03, 2025

Validation of the International Medullary Thyroid Carcinoma Grading System in Patients with Distant Metastases.

Journal: Thyroid : official journal of the American Thyroid Association

Published: October 29, 2025

The rise of thyroid cancer incidence in adolescents and young adults.

Journal: The lancet. Diabetes & endocrinology

Published: October 08, 2025

Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +/- dabrafenib followed by radioactive iodine.

Journal: Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)

Published: July 03, 2025

The unique signature of tyrosine kinase inhibitor-induced hypothyroidism.

Journal: The lancet. Diabetes & endocrinology

Published: May 17, 2025

Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?

Journal: European thyroid journal

Published: October 15, 2024

Natural history of medullary thyroid carcinoma in MEN 2 patients carrying a variant at codon 804 in the RET proto-oncogene: A study by the French Neuroendocrine Tumor Group (GTE).

Journal: Annales d'endocrinologie

Published: September 06, 2024

Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.

Journal: The lancet. Diabetes & endocrinology

Published: June 14, 2024

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).

Journal: Frontiers in endocrinology

Published: March 19, 2024

Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.

Journal: Endocrine-related cancer

Published: December 23, 2023